Skip to main content

Table 1 Relative susceptibility (RS) and relative efficacy (RE)

From: Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors

Condition

RS(24)

RE(24)

RS(48)

RE(48)

(K-Ras, REGO)

2.31

0.23

1.64

0.31

(K-Ras, PI3K-i)

0.59

0.53

0.52

1.10

(K-Ras, MEK-i)

1.22

0.51

1.27

0.48

(K-Ras/PI3K, REGO)

0.77

1.28

1.05

1.06

(K-Ras/PI3K, PI3K-i)

1.38

0.35

0.88

0.93

(K-Ras/PI3K, MEK-i)

0.99

0.70

1.25

0.77

  1. Two measures are calculated in the original space for two different times following treatment
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us